Godavari Biorefineries shares locked in 5% upper circuit on getting patent for anti cancer molecule

Shares of Godavari Biorefineries, the ethanol-based chemicals maker, were locked in 5% upper circuit at ₹258.90 on BSE after the company post market hours on Thursday informed exchanges that it has been granted patent in Europe for anticancer molecule. On the National Stock Exchange, Godavari Biorefineries shares rose by their daily maximum limit of 5% at ₹256.75.

"This is to inform that the Company has been granted a patent in Europe for our novel anticancer molecule. This patent is now validated in Spain, UK as a Unitary Patent. The patent subject area is “Anti-Cancer Research Segment" the patent cover very potent anticancer compound with proven efficacy on cancer and cancer stem cell," Godavari Biorefineries said in an exchange filing.

There were pending buy orders for 9,411 shares on the BSE with no sellers.

Godavari Biorefineries Q4 earnings

Godavari Biorefineries in fourth quarter of financial year 2024-25 reported net profit of ₹72 crore, marking an increase of 11% from ₹65 crore in the same period last year.

Its revenue from operations, however, declined 6% to ₹580 crore as against ₹615 crore in the year-ago period.

The company's operating profit came in at ₹122 crore and margin improved 12.4% from 10.6%.

Godavari Biorefineries share performance

Godavari Biorefineries shares have so far this year declined 18% underperforming the BSE SmallCap index which is down 0.8% year-to-date.

As of 3:15 pm, Godavari Biorefineries shares were locked in upper circuit.